Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2011

View Archived Issues

Photocross-linked biosynthetic implants provide new tool for soft tissue reconstruction

Scientists genetically engineer E. coli to detect and kill P. aeruginosa

Human monoclonal antibody neutralizes influenza A group 2 viruses

Ranbaxy discloses new DPP IV/ACE inhibitors

New antitumor agents synthesized by Kyowa Hakko Kirin

Vertex discloses new inhibitors of PKC-theta

Novel antitumor agents disclosed by Chinese and U.S. team

New vitamin D analogues claimed

Cynapsus provides update on proposed acquisition of Adagio Pharmaceuticals

Afexa Life Sciences reports on LIP-01 trial in cholesterol management

Adamas Pharmaceuticals begins phase II/III study of ADS-5102

Shionogi advances acquisition of C&O Pharmaceutical Technology

Endo Pharmaceuticals terminates collaboration with Gruenenthal

FDA grants fast track status to DARA's KRN-5500

Kinex Pharmaceuticals begins phase I trial of KX2-391 in AML

Curis doses first patient in CUDC-101 head and neck cancer study

MAA accepted and NDA submitted for ridaforolimus

Hydrogen sulfide replacement may protect against complications of diabetes

Phase II trial of Cell Therapeutics' Opaxio opens enrollment

Furiex closes loan agreement to support development of clinical-stage products

NPS Pharmaceuticals submits CMC section of Gattex NDA to FDA

Antigen Express presents phase II data on anticancer vaccine AE-37 in breast cancer

FDA clears IND to conduct clinical studies of lasmiditan

FDA approves Marshall Edwards' IND for lead NADH oxidase inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...